Urogen Pharma (URGN) just unveiled an update.
UroGen Pharma Ltd. has been notified by Teva Pharmaceuticals of their intent to produce a generic version of UroGen’s drug, Jelmyto, used for treating urothelial cancers. Teva is challenging the validity of UroGen’s patents on Jelmyto, which are set to expire in 2031. UroGen’s CEO, Liz Barrett, expressed confidence in the company’s patent portfolio and its pioneering role in the market, suggesting they are ready to defend their intellectual property rights.
See more insights into URGN stock on TipRanks’ Stock Analysis page.
